Table 4. Change in Vital Signs From Baseline to End of Treatment*

Varenicline (n=304)Placebo (n=284)Difference Between Groups at Week 1295% CI for Difference
BaselineWeek 12Difference (Baseline to Week 12)BaselineWeek 12Difference (Baseline to Week 12)
*Limited to participants with measurements at both baseline and Week 12.
†Average of 2 baseline measurements.
‡Week 12 (end of treatment).
Systolic blood pressure, mean (SD), mm Hg126.8 (16.2)125.9 (15.3)−0.8 (15.2)126.8 (15.5)125.5 (16.1)−1.3 (13.3)0.5−1.8–2.9
Diastolic blood pressure, mean (SD), mm Hg76.9 (9.6)77.9 (9.4)1.1 (9.6)77.2 (9.5)76.7 (9.5)−0.5 (9.1)1.60.04–3.1
Pulse rate, mean (SD), bpm72.5 (11.3)69.9 (11.1)−2.4 (9.9)73.0 (11.8)70.1 (11.7)−2.8 (9.9)0.4−1.3–2.0